Next Article in Journal
Preoperative Assessment of Upper Extremity Secondary Lymphedema
Previous Article in Journal
Preclinical Models of Craniospinal Irradiation for Medulloblastoma
Previous Article in Special Issue
Long-Term Outcomes after Use of Perioperative Glucocorticoids in Patients Undergoing Cancer Surgery: A Systematic Review and Meta-Analysis
Open AccessArticle

Mu Opioid Receptor 1 (MOR-1) Expression in Colorectal Cancer and Oncological Long-Term Outcomes: A Five-Year Retrospective Longitudinal Cohort Study

1
Department of Anesthesiology, Hospital Universitarii Politécnic La Fe, Avenida de Fernando Abril Martorell, 106, 46026 Valencia, Spain
2
Perioperative Medicine Research Group, Instituto de Investigación Sanitaria La Fe (IISlaFe), Avenida de Fernando Abril Martorell, 106, 46026 Valencia, Spain
3
EU-COST Action 15204, Euro-Periscope, Avenue Louise 149, 1050 Brussels, Belgium
4
Department of Pathology, Hospital Universitari i Politécnic La Fe, Avenida de Fernando Abril Martorell, 106, 46026 Valencia, Spain
5
Department of Digestive Surgery, Hospital General Universitario de Elche, Calle Almazara, 11, 03203 Elche, Spain
6
INCLIVA Biomedical Research Institute, Avenida de Menéndez y Pelayo, 4, 46010 Valencia, Spain
7
Department Medical Oncology, University of Valencia INCLIVA-Hospital Clínico de Valencia-CIBERONC, Avenida de Menéndezy Pelayo, 4, 46010 Valencia, Spain
8
Department of Anesthesiology & Perioperative Medicine, The University of Texas–MD Anderson Cancer Center, Houston, TX 77030, USA
9
Anesthesia & Surgical Oncology Research Group, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 134; https://doi.org/10.3390/cancers12010134
Received: 1 December 2019 / Revised: 1 January 2020 / Accepted: 2 January 2020 / Published: 5 January 2020
Preclinical evidence has shown increased expression of mu opioid receptor 1 (MOR-1) in colorectal cancer although its association with disease-free and overall survival (DFS and OS) has not been investigated. We hypothesized that MOR-1 was overexpressed in tumor samples compared to normal tissue and this was associated with decreased DFS and OS. We carried out a retrospective study assessing the association of MOR-1 tumor expression with long-term outcomes by immunohistochemistry in normal and tumor samples from 174 colorectal cancer patients. The primary endpoint was five years of DFS. Secondary endpoints were five years of OS, the difference in MOR-1 expression between normal and tumor tissue and the occurrence of postoperative complications. Multivariable Cox regression showed no significant association between MOR-1 expression and DFS (HR 0.791, 95% CI 0.603–1.039, p = 0.092). MOR-1 expression was higher in tumor tissue compared to non-tumor tissue. No associations were found between MOR-1 expression and OS or postoperative complications. These findings suggest that although MOR-1 is over-expressed in colorectal cancer samples there is no association to increased risk of recurrence or mortality. Future studies are warranted to elucidate the role of cancer stage, genetic polymorphism, and quantitative assessment of MOR-1 over-expression on long-term outcomes in colorectal cancer. View Full-Text
Keywords: colon cancer; immunohistochemistry; mu opioid receptors; perioperative opioid; perioperative medicine; disease free survival colon cancer; immunohistochemistry; mu opioid receptors; perioperative opioid; perioperative medicine; disease free survival
Show Figures

Graphical abstract

MDPI and ACS Style

Díaz-Cambronero, O.; Mazzinari, G.; Giner, F.; Belltall, A.; Ruiz-Boluda, L.; Marqués-Marí, A.; Sánchez-Guillén, L.; Eroles, P.; Cata, J.P.; Argente-Navarro, M.P. Mu Opioid Receptor 1 (MOR-1) Expression in Colorectal Cancer and Oncological Long-Term Outcomes: A Five-Year Retrospective Longitudinal Cohort Study. Cancers 2020, 12, 134.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop